We are interested in dissecting new cellular signaling pathways that control the proliferation and survival of solid paediatric and adult cancers. We collaborate with academics and Biopharma Companies to perform preclinical development of new anticancer drugs that sensitize tumor to standard anticancer treatments, including chemotherapy and immunotherapy. Specifically, we are interested in deciphering the role of the new MAP kinase ERK5 in cancer proliferation and survival, as well as in tumor immunosuppression. We are also interested in modulation of autophagy and endoplasmic reticulum (ER) stress as new strategies to tackle cancer.
